CoChat

Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data

Open access
Merritt, Kate, McGuire, Philip K., Egerton, Alice, 1H-MRS in Schizophrenia Investigators, Aleman, André, Block, Wolfgang, Bloemen, Oswald J. N., Borgan, Faith, Bustillo, Juan R., Capizzano, Aristides A., Coughlin, Jennifer Marie, De la Fuente-Sandoval, Camilo, Demjaha, Arsime, Dempster, Kara, Do, Kim Q., Du, Fei, Falkai, Peter, Galinska-Skok, Beata, Gallinat, Jurgen, Gasparovic, Charles, Ginestet, Cedric E., Goto, Naoki, Graff-Guerrero, Ariel, Ho, Beng Choon, Howes, Oliver D., Jauhar, Sameer, Jeon, Peter, Kato, Tadafumi, Kaufmann, Charles A., Kegeles, Lawrence S., Keshavan, Matcheri, Kim, Sang-Young, Kunugi, Hiroshi, Lauriello, John, Liemburg, Edith Jantine, Mcilwain, Meghan E., Modinos, Gemma, Mouchlianitis, Elias D., Nakamura, Jun, Nenadic, Igor, Öngür, Dost, Ota, Miho, Palaniyappan, Lena, Pantelis, Christos, Plitman, Eric, Posporelis, Sotirios, Purdon, Scot E., Reichenbach, Jürgen R., Renshaw, Perry F., Russell, Bruce R., Sawa, Akira, Schaefer, Martin, Shungu, Dikoma C., Smesny, Stefan, Stanley, Jeffrey A., Stone, James M., Szulc, Agata, Taylor, Reggie, Thakkar, Katy, Théberge, Jean, Tibbo, Philip G., van Amelsvoort, Therese, Walecki, Jerzy, Williamson, Peter C., Wood, Stephen James, Xin, Lijing, Yamasue, Hidenori · 2021 · JAMA Psychiatry
Cited by 141

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Importance: Proton magnetic resonance spectroscopy (1H-MRS) studies indicate that altered brain glutamatergic function may be associated with the pathophysiology of schizophrenia and the response to antipsychotic treatment. However, the association of altered glutamatergic function with clinical and demographic factors is unclear. Objective: To assess the associations of age, symptom severity, level of functioning, and antipsychotic treatment with brain glutamatergic metabolites. Data Sources: The MEDLINE database was searched to identify journal articles published between January 1, 1980, and June 3, 2020, using the following search terms: MRS or magnetic resonance spectroscopy and (1) schizophrenia or (2) psychosis or (3) UHR or (4) ARMS or (5) ultra-high risk or (6) clinical high risk or (7) genetic high risk or (8) prodrome* or (9) schizoaffective. Authors of 114 1H-MRS studies measuring glutamate (Glu) levels in patients with schizophrenia were contacted between January 2014 and June 2020 and asked to provide individual participant data. Study Selection: In total, 45 1H-MRS studies contributed data. Data Extraction and Synthesis: Associations of Glu, Glu plus glutamine (Glx), or total creatine plus phosphocreatine levels with age, antipsychotic medication dose, symptom severity, and functioning were assessed using linear mixed models, with study as a random factor. Main Outcomes and Measures: Glu, Glx, and Cr values in the medial frontal cortex (MFC) and medial temporal lobe (MTL). Results: In total, 42 studies were included, with data for 1251 patients with schizophrenia (mean [SD] age, 30.3 [10.4] years) and 1197 healthy volunteers (mean [SD] age, 27.5 [8.8] years). The MFC Glu (F1,1211.9 = 4.311, P = .04) and Glx (F1,1079.2 = 5.287, P = .02) levels were lower in patients than in healthy volunteers, and although creatine levels appeared lower in patients, the difference was not significant (F1,1395.9 = 3.622, P = .06). In both patients and volunteers, the MFC Glu level was negatively associated with age (Glu to Cr ratio, F1,1522.4 = 47.533, P < .001; cerebrospinal fluid-corrected Glu, F1,1216.7 = 5.610, P = .02), showing a 0.2-unit reduction per decade. In patients, antipsychotic dose (in chlorpromazine equivalents) was negatively associated with MFC Glu (estimate, 0.10 reduction per 100 mg; SE, 0.03) and MFC Glx (estimate, -0.11; SE, 0.04) levels. The MFC Glu to Cr ratio was positively associated with total symptom severity (estimate, 0.01 per 10 points; SE, 0.005) and positive symptom severity (estimate, 0.04; SE, 0.02) and was negatively associated with level of global functioning (estimate, 0.04; SE, 0.01). In the MTL, the Glx to Cr ratio was positively associated with total symptom severity (estimate, 0.06; SE, 0.03), negative symptoms (estimate, 0.2; SE, 0.07), and worse Clinical Global Impression score (estimate, 0.2 per point; SE, 0.06). The MFC creatine level increased with age (estimate, 0.2; SE, 0.05) but was not associated with either symptom severity or antipsychotic medication dose. Conclusions and Relevance: Findings from this mega-analysis suggest that lower brain Glu levels in patients with schizophrenia may be associated with antipsychotic medication exposure rather than with greater age-related decline. Higher brain Glu levels may act as a biomarker of illness severity in schizophrenia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamapsychiatry.2021.0380

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 76

  1. Sydnor, 2020, A meta-analysis of ultra-high field glutamate, glutamine, GABA and glutathione 1HMRS in psychosis: Implications for studies of psychosis risk., Schizophr Res, 226, 61, 10.1016/j.schres.2020.06.028 · DOI · Paper page
  2. Egerton, 2018, Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H-MRS study (OPTiMiSE)., Mol Psychiatry, 23, 2145, 10.1038/s41380-018-0082-9 · DOI
  3. Bartha, 1997, Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy., Arch Gen Psychiatry, 54, 959, 10.1001/archpsyc.1997.01830220085012 · DOI · Paper page
  4. Ohrmann, 2005, Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study., Schizophr Res, 73, 153, 10.1016/j.schres.2004.08.021 · DOI
  5. Natsubori, 2014, Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia., Schizophr Bull, 40, 1128, 10.1093/schbul/sbt124 · DOI · Paper page
  6. Lutkenhoff, 2010, Proton MRS in twin pairs discordant for schizophrenia., Mol Psychiatry, 15, 308, 10.1038/mp.2008.87 · DOI
  7. Tayoshi, 2009, Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS)., Schizophr Res, 108, 69, 10.1016/j.schres.2008.11.014 · DOI
  8. Théberge, 2003, Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS., Am J Psychiatry, 160, 2231, 10.1176/appi.ajp.160.12.2231 · DOI · Paper page
  9. Palaniyappan, 2017, Progressive cortical reorganisation: a framework for investigating structural changes in schizophrenia., Neurosci Biobehav Rev, 79, 1, 10.1016/j.neubiorev.2017.04.028 · DOI
  10. Wijtenburg, 2017, Altered glutamate and regional cerebral blood flow levels in schizophrenia: a 1H-MRS and pCASL study., Neuropsychopharmacology, 42, 562, 10.1038/npp.2016.172 · DOI
  11. Bustillo, 2017, Glutamatergic and neuronal dysfunction in gray and white matter: a spectroscopic imaging study in a large schizophrenia sample., Schizophr Bull, 43, 611
  12. Aoyama, 2011, Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia., Br J Psychiatry, 198, 448, 10.1192/bjp.bp.110.079608 · DOI · Paper page
  13. Egerton, 2017, Effects of antipsychotic administration on brain glutamate in schizophrenia: a systematic review of longitudinal 1H-MRS studies., Front Psychiatry, 8, 66, 10.3389/fpsyt.2017.00066 · DOI · Paper page
  14. Merritt, 2013, Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis., Front Psychiatry, 4, 151, 10.3389/fpsyt.2013.00151 · DOI · Paper page
  15. Ota, 2012, Glutamatergic changes in the cerebral white matter associated with schizophrenic exacerbation., Acta Psychiatr Scand, 126, 72, 10.1111/acps.2012.126.issue-1 · doi:10.1111/acps.2012.126.issue-1
  16. Egerton, 2012, Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia., Neuropsychopharmacology, 37, 2515, 10.1038/npp.2012.113 · DOI · Paper page
  17. Mouchlianitis, 2016, Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive., Schizophr Bull, 42, 744, 10.1093/schbul/sbv151 · DOI · Paper page
  18. NPJ Schizophr
  19. Verbyla, 2019, A note on model selection using information criteria for general linear models estimated using REML., Aust N Z J Stat, 61, 39, 10.1111/anzs.2019.61.issue-1 · doi:10.1111/anzs.2019.61.issue-1
  20. de la Fuente-Sandoval, 2011, Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis., Neuropsychopharmacology, 36, 1781, 10.1038/npp.2011.65 · DOI · Paper page
  21. Modinos, 2018, Cortical GABA in subjects at ultra-high risk of psychosis: relationship to negative prodromal symptoms., Int J Neuropsychopharmacol, 21, 114, 10.1093/ijnp/pyx076 · DOI
  22. de la Fuente-Sandoval, 2015, Cortico-striatal GABAergic and glutamatergic dysregulations in subjects at ultra-high risk for psychosis investigated with proton magnetic resonance spectroscopy., Int J Neuropsychopharmacol, 19, 10.1093/ijnp/pyv105 · DOI
  23. Bustillo, 2014, Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T., JAMA Psychiatry, 71, 265, 10.1001/jamapsychiatry.2013.3939 · DOI · Paper page
  24. Coughlin, 2015, Decoupling of N-acetyl-aspartate and glutamate within the dorsolateral prefrontal cortex in schizophrenia., Curr Mol Med, 15, 176, 10.2174/1566524015666150303104811 · DOI
  25. Posporelis, 2018, Decoupling of brain temperature and glutamate in recent onset of schizophrenia: a 7T proton magnetic resonance spectroscopy study., Biol Psychiatry Cogn Neurosci Neuroimaging, 3, 248
  26. Taylor, 2017, Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T., BJPsych Open, 3, 6, 10.1192/bjpo.bp.116.003756 · DOI
  27. Stanley, 1996, An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients., Schizophr Bull, 22, 597, 10.1093/schbul/22.4.597 · DOI · Paper page
  28. Gallinat, 2016, Cross-sectional study of glutamate in the anterior cingulate and hippocampus in schizophrenia., Schizophr Bull, 42, 425, 10.1093/schbul/sbv124 · DOI
  29. Stanley, 2007, Reduced N-acetyl-aspartate levels in schizophrenia patients with a younger onset age: a single-voxel 1H spectroscopy study., Schizophr Res, 93, 23, 10.1016/j.schres.2007.03.028 · DOI
  30. Xin, 2016, Genetic polymorphism associated prefrontal glutathione and its coupling with brain glutamate and peripheral redox status in early psychosis., Schizophr Bull, 42, 1185, 10.1093/schbul/sbw038 · DOI · Paper page
  31. Smesny, 2015, Glutamatergic dysfunction linked to energy and membrane lipid metabolism in frontal and anterior cingulate cortices of never treated first-episode schizophrenia patients., Schizophr Res, 168, 322, 10.1016/j.schres.2015.07.013 · DOI
  32. Liemburg, 2016, Prefrontal NAA and Glx levels in different stages of psychotic disorders: a 3T 1H-MRS study., Sci Rep, 6, 21873, 10.1038/srep21873 · DOI · Paper page
  33. Kim, 2018, In vivo brain glycine and glutamate concentrations in patients with first-episode psychosis measured by echo time-averaged proton magnetic resonance spectroscopy at 4T., Biol Psychiatry, 83, 484, 10.1016/j.biopsych.2017.08.022 · DOI
  34. Borgan, 2019, Glutamate levels in the anterior cingulate cortex in un-medicated first episode psychosis: a proton magnetic resonance spectroscopy study., Sci Rep, 9, 8685, 10.1038/s41598-019-45018-0 · DOI
  35. Plitman, 2016, Elevated myo-inositol, choline, and glutamate levels in the associative striatum of antipsychotic-naive patients with first-episode psychosis: a proton magnetic resonance spectroscopy study with implications for glial dysfunction., Schizophr Bull, 42, 415, 10.1093/schbul/sbv118 · DOI · Paper page
  36. Goto, 2012, Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia., Neuropsychiatr Dis Treat, 8, 119
  37. Théberge, 2002, Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers., Am J Psychiatry, 159, 1944, 10.1176/appi.ajp.159.11.1944 · DOI · Paper page
  38. Tibbo, 2013, 3-T proton magnetic spectroscopy in unmedicated first episode psychosis: a focus on creatine., Magn Reson Med, 69, 613, 10.1002/mrm.24291 · DOI
  39. Galinska, 2009, Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophrenia., Med Sci Monit, 15, CR82
  40. Wood, 2008, A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naïve and early-treated first episode psychosis., Schizophr Res, 102, 163, 10.1016/j.schres.2008.03.012 · DOI
  41. Wood, 2007, Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3 T., Schizophr Res, 94, 328, 10.1016/j.schres.2007.05.008 · DOI
  42. Kegeles, 2000, Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies., Psychiatry Res, 98, 163, 10.1016/S0925-4927(00)00044-5 · DOI
  43. Szulc, 2011, Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment., Pharmacopsychiatry, 44, 148, 10.1055/s-0031-1279739 · DOI · Paper page
  44. Goldstein, 2015, Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia., Int J Neuropsychopharmacol, 18, 10.1093/ijnp/pyu117 · DOI
  45. Block, Neurosci Lett
  46. Öngür, 2010, Elevated gamma-aminobutyric acid levels in chronic schizophrenia., Biol Psychiatry, 68, 667, 10.1016/j.biopsych.2010.05.016 · DOI · Paper page
  47. Öngür, 2008, Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania., Biol Psychiatry, 64, 718, 10.1016/j.biopsych.2008.05.014 · DOI · Paper page
  48. Yamasue, 2003, Drug-induced parkinsonism in relation to choline-containing compounds measured by 1H-MR spectroscopy in putamen of chronically medicated patients with schizophrenia., Int J Neuropsychopharmacol, 6, 353, 10.1017/S1461145703003687 · DOI
  49. Modinos, 2018, Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis., Neuropsychopharmacology, 43, 2652, 10.1038/s41386-017-0004-6 · DOI · Paper page
  50. Demjaha, 2014, Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function., Biol Psychiatry, 75, e11, 10.1016/j.biopsych.2013.06.011 · DOI · Paper page
  51. Egerton, 2014, Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis., Neuropsychopharmacology, 39, 2891, 10.1038/npp.2014.143 · DOI · Paper page
  52. Capizzano, 2011, Magnetic resonance spectroscopy of limbic structures displays metabolite differences in young unaffected relatives of schizophrenia probands., Schizophr Res, 131, 4, 10.1016/j.schres.2011.05.024 · DOI
  53. Bloemen, 2011, Hippocampal glutamate levels and striatal dopamine D2/3 receptor occupancy in subjects at ultra high risk of psychosis., Biol Psychiatry, 70, e1, 10.1016/j.biopsych.2010.11.030 · DOI
  54. Dempster, 2020, Early treatment response in first episode psychosis: a 7-T magnetic resonance spectroscopic study of glutathione and glutamate., Mol Psychiatry, 25, 1640, 10.1038/s41380-020-0704-x · DOI
  55. Bloemen, 2010, White-matter markers for psychosis in a prospective ultra-high-risk cohort., Psychol Med, 40, 1297, 10.1017/S0033291709991711 · DOI · Paper page
  56. Roalf, 2020, A quantitative meta-analysis of brain glutamate metabolites in aging., Neurobiol Aging, 95, 240, 10.1016/j.neurobiolaging.2020.07.015 · DOI
  57. Angelie, 2001, Regional differences and metabolic changes in normal aging of the human brain: proton MR spectroscopic imaging study., AJNR Am J Neuroradiol, 22, 119
  58. Gruber, 2008, Metabolic changes in the normal ageing brain: consistent findings from short and long echo time proton spectroscopy., Eur J Radiol, 68, 320, 10.1016/j.ejrad.2007.08.038 · doi:10.1016/j.ejrad.2007.08.038
  59. Chang, Life Sci
  60. Pfefferbaum, 1999, In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging., Magn Reson Med, 41, 276, 10.1002/(ISSN)1522-2594 · DOI · Paper page
  61. Brooks, 2001, A proton magnetic resonance spectroscopy study of age-related changes in frontal lobe metabolite concentrations., Cereb Cortex, 11, 598, 10.1093/cercor/11.7.598 · DOI · Paper page
  62. Mrak, 1997, Aging-associated changes in human brain., J Neuropathol Exp Neurol, 56, 1269, 10.1097/00005072-199712000-00001 · DOI · Paper page
  63. Terry, 1987, Neocortical cell counts in normal human adult aging., Ann Neurol, 21, 530, 10.1002/(ISSN)1531-8249 · DOI · Paper page
  64. Legind, 2019, Heritability of cerebral glutamate levels and their association with schizophrenia spectrum disorders: a 1[H]-spectroscopy twin study., Neuropsychopharmacology, 44, 581, 10.1038/s41386-018-0236-0 · DOI
  65. Jeon, Progressive changes in glutamate concentration in early stages of schizophrenia: a longitudinal 7-Tesla MRS study., Schizophr Bull
  66. Neural Plast
  67. de la Fuente-Sandoval, 2018, Prefrontal and striatal gamma-aminobutyric acid levels and the effect of antipsychotic treatment in first-episode psychosis patients., Biol Psychiatry, 83, 475, 10.1016/j.biopsych.2017.09.028 · DOI
  68. Iwata, 2019, Glutamatergic neurometabolite levels in patients with ultra-treatment-resistant schizophrenia: a cross-sectional 3T proton magnetic resonance spectroscopy study., Biol Psychiatry, 85, 596, 10.1016/j.biopsych.2018.09.009 · DOI
  69. Tarumi, 2020, Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study., Neuropsychopharmacology, 45, 632, 10.1038/s41386-019-0589-z · DOI
  70. Egerton, Dopamine and glutamate in antipsychotic-responsive compared with antipsychotic-nonresponsive psychosis: a multicenter positron emission tomography and magnetic resonance spectroscopy study (STRATA)., Schizophr Bull
  71. Grace, 2019, The circuitry of dopamine system regulation and its disruption in schizophrenia: insights into treatment and prevention., Schizophr Bull, 45, 148, 10.1093/schbul/sbx199 · DOI · Paper page
  72. Boedhoe, 2019, An empirical comparison of meta- and mega-analysis with data from the ENIGMA Obsessive-Compulsive Disorder Working Group., Front Neuroinform, 12, 102, 10.3389/fninf.2018.00102 · DOI · Paper page
  73. Tognin, 2020, Towards precision medicine in psychosis: benefits and challenges of multimodal multicenter studies—PSYSCAN: translating neuroimaging findings from research into clinical practice., Schizophr Bull, 46, 432, 10.1093/schbul/sbz067 · DOI · Paper page
  74. Choe, 1996, Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy., Invest Radiol, 31, 345, 10.1097/00004424-199606000-00006 · DOI · Paper page
  75. Kubota, 2020, Treatment effects on neurometabolite levels in schizophrenia: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies., Schizophr Res, 222, 122, 10.1016/j.schres.2020.03.069 · DOI
  76. Wickham, 2009, ggplot2: Elegant Graphics for Data Analysis, 10.1007/978-0-387-98141-3 · DOI · Paper page

Cited by

See all 141

Metadata

Authors
Merritt, K., McGuire, P. K., Egerton, A., 1H-MRS in Schizophrenia Investigators, Aleman, A., Block, W., Bloemen, O. J. N., Borgan, F., Bustillo, J. R., Capizzano, A. A., Coughlin, J. M., De la Fuente-Sandoval, C., Demjaha, A., Dempster, K., Do, K. Q., Du, F., Falkai, P., Galinska-Skok, B., Gallinat, J., Gasparovic, C., Ginestet, C. E., Goto, N., Graff-Guerrero, A., Ho, B. C., Howes, O. D., Jauhar, S., Jeon, P., Kato, T., Kaufmann, C. A., Kegeles, L. S., Keshavan, M., Kim, S.-Y., Kunugi, H., Lauriello, J., Liemburg, E. J., Mcilwain, M. E., Modinos, G., Mouchlianitis, E. D., Nakamura, J., Nenadic, I., Öngür, D., Ota, M., Palaniyappan, L., Pantelis, C., Plitman, E., Posporelis, S., Purdon, S. E., Reichenbach, J. R., Renshaw, P. F., Russell, B. R., Sawa, A., Schaefer, M., Shungu, D. C., Smesny, S., Stanley, J. A., Stone, J. M., Szulc, A., Taylor, R., Thakkar, K., Théberge, J., Tibbo, P. G., van Amelsvoort, T., Walecki, J., Williamson, P. C., Wood, S. J., Xin, L., & Yamasue, H.
Venue
JAMA Psychiatry
Published
2021-06-01
Volume
78
Issue
6
Pages
667
ISSN
2168-622X (ISSN-L)
OpenAlex
W3155984011
Cited by
141
References
14
FWCI
14.12
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.